StructurE-unbiased Library for Exploratory disCovery of Targets
StructurE-unbiased Library for Exploratory disCovery of Targets
“Unbiased Discovery”
“Unlike traditional target-based approaches, SELECT uses phenotypic screening to uncover unexpected and novel biological mechanisms.”
SELECT Screening Services
Phenotypic screening for antiviral and anticancer drug discovery.
Broad-spectrum antiviral panel covering 8 virus families
Advancing Antiviral Discovery Through Phenotypic Screening
The SELECT platform applies a target-agnostic phenotypic screening strategy to identify compounds with antiviral activity across a curated panel of viruses from eight distinct families, including DNA and RNA viruses. We welcome molecules with broad or narrow activity profiles, and value both novel and well-established mechanisms of action. This inclusive approach supports the discovery of innovative therapeutic leads, chemical probes, and validated drug candidates, contributing to a deeper understanding of viral biology and treatment strategies.
Human cancer cell line panel with high clinical relevance
Exploring Antitumor Activity in Clinically Relevant Cancer Models
Our cancer screening panel comprises a diverse set of human cancer cell lines representing major tissue types and high medical need. SELECT’s phenotypic-first approach allows for the identification of compounds with potent antiproliferative effects, independent of known targets. This strategy facilitates the discovery of novel cancer vulnerabilities and mechanisms of action, providing a foundation for future drug development and precision oncology.
Solid Tumors
Our panel of solid tumor models includes pancreatic adenocarcinoma (Capan‑1), colorectal carcinoma (HCT 116), glioblastoma (LN‑229), and non-small cell lung carcinoma (NCI‑H460), providing clinically relevant diversity for anticancer compound screening.
Hematological Cancers
Our hematological panel includes models of acute lymphoblastic leukemia (MOLT‑4), acute promyelocytic leukemia (HL‑60), chronic myeloid leukemia (K562), and mantle cell lymphoma (Z‑138), enabling comprehensive screening across diverse blood cancers.
Integrated Screening Approach
SELECT combines a target-agnostic phenotypic screening strategy with advanced high-throughput technologies to accelerate antiviral and anticancer drug discovery.
Unbiased Discovery
Using disease-relevant models, our screening identifies compounds with novel biological activity, without prior assumptions about molecular targets.
Smart Data Management
Integrated software platforms ensure seamless compound tracking and analysis.
Mechanistic Insight
Enables the identification of chemical probes and therapeutic leads with unknown or unexpected mechanisms of action.